Literature DB >> 22892536

Intentions to receive individual results from whole-genome sequencing among participants in the ClinSeq study.

Flavia M Facio1, Haley Eidem, Tyler Fisher, Stephanie Brooks, Amy Linn, Kimberly A Kaphingst, Leslie G Biesecker, Barbara B Biesecker.   

Abstract

Genome sequencing has been rapidly integrated into clinical research and is currently marketed to health-care practitioners and consumers alike. The volume of sequencing data generated for a single individual and the wide range of findings from whole-genome sequencing raise critical questions about the return of results and their potential value for end-users. We conducted a mixed-methods study of 311 sequential participants in the NIH ClinSeq study to assess general preferences and specific attitudes toward learning results. We tested how these variables predicted intentions to receive results within four categories of findings ranging from medically actionable to variants of unknown significance. Two hundred and ninety-four participants indicated a preference to learn their genome sequencing results. Most often, participants cited disease prevention as their reason, including intention to change their lifestyle behaviors. Participants held positive attitudes, strongly perceived social norms and strong intentions to learn results, although there were significant mean differences among four categories of findings (P<0.01). Attitudes and social norms for medically actionable and carrier results were most similar and rated the highest. Participants distinguished among the types and quality of information they may receive, despite strong intentions to learn all results presented. These intentions were motivated by confidence in their ability to use the information to prevent future disease and a belief in the value of even uninterpretable information. It behooves investigators to facilitate participants' desire to learn a range of information from genomic sequencing while promoting realistic expectations for its clinical and personal utility.

Entities:  

Mesh:

Year:  2012        PMID: 22892536      PMCID: PMC3573208          DOI: 10.1038/ejhg.2012.179

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  25 in total

Review 1.  Exome sequencing: a transformative technology.

Authors:  Andrew B Singleton
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

Review 2.  Annotating individual human genomes.

Authors:  Ali Torkamani; Ashley A Scott-Van Zeeland; Eric J Topol; Nicholas J Schork
Journal:  Genomics       Date:  2011-08-02       Impact factor: 5.736

3.  Motivators for participation in a whole-genome sequencing study: implications for translational genomics research.

Authors:  Flavia M Facio; Stephanie Brooks; Johanna Loewenstein; Susannah Green; Leslie G Biesecker; Barbara B Biesecker
Journal:  Eur J Hum Genet       Date:  2011-07-06       Impact factor: 4.246

4.  Personal genome research : what should the participant be told?

Authors:  Amy L McGuire; James R Lupski
Journal:  Trends Genet       Date:  2010-04-08       Impact factor: 11.639

5.  Modelling decisions to undergo genetic testing for susceptibility to common health conditions: an ancillary study of the Multiplex Initiative.

Authors:  Christopher H Wade; Shoshana Shiloh; Samuel W Woolford; J Scott Roberts; Sharon Hensley Alford; Theresa M Marteau; Barbara B Biesecker
Journal:  Psychol Health       Date:  2011-06-09

6.  Exome sequencing allows for rapid gene identification in a Charcot-Marie-Tooth family.

Authors:  Gladys Montenegro; Eric Powell; Jia Huang; Fiorella Speziani; Yvonne J K Edwards; Gary Beecham; William Hulme; Carly Siskind; Jeffery Vance; Michael Shy; Stephan Züchner
Journal:  Ann Neurol       Date:  2011-01-20       Impact factor: 10.422

7.  Ethical and practical guidelines for reporting genetic research results to study participants: updated guidelines from a National Heart, Lung, and Blood Institute working group.

Authors:  Richard R Fabsitz; Amy McGuire; Richard R Sharp; Mona Puggal; Laura M Beskow; Leslie G Biesecker; Ebony Bookman; Wylie Burke; Esteban Gonzalez Burchard; George Church; Ellen Wright Clayton; John H Eckfeldt; Conrad V Fernandez; Rebecca Fisher; Stephanie M Fullerton; Stacey Gabriel; Francine Gachupin; Cynthia James; Gail P Jarvik; Rick Kittles; Jennifer R Leib; Christopher O'Donnell; P Pearl O'Rourke; Laura Lyman Rodriguez; Sheri D Schully; Alan R Shuldiner; Rebecca K F Sze; Joseph V Thakuria; Susan M Wolf; Gregory L Burke
Journal:  Circ Cardiovasc Genet       Date:  2010-12

8.  Future health applications of genomics: priorities for communication, behavioral, and social sciences research.

Authors:  Colleen M McBride; Deborah Bowen; Lawrence C Brody; Celeste M Condit; Robert T Croyle; Marta Gwinn; Muin J Khoury; Laura M Koehly; Bruce R Korf; Theresa M Marteau; Kenneth McLeroy; Kevin Patrick; Thomas W Valente
Journal:  Am J Prev Med       Date:  2010-05       Impact factor: 5.043

9.  Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time.

Authors:  Jonathan S Berg; Muin J Khoury; James P Evans
Journal:  Genet Med       Date:  2011-06       Impact factor: 8.822

10.  Exome sequencing supports a de novo mutational paradigm for schizophrenia.

Authors:  Bin Xu; J Louw Roos; Phillip Dexheimer; Braden Boone; Brooks Plummer; Shawn Levy; Joseph A Gogos; Maria Karayiorgou
Journal:  Nat Genet       Date:  2011-08-07       Impact factor: 38.330

View more
  97 in total

1.  Discussing molecular testing in oncology care: Comparing patient and physician information preferences.

Authors:  Ana P M Pinheiro; Rachel H Pocock; Jeffrey M Switchenko; Margie D Dixon; Walid L Shaib; Suresh S Ramalingam; Rebecca D Pentz
Journal:  Cancer       Date:  2017-01-31       Impact factor: 6.860

Review 2.  Return of individual research results and incidental findings: facing the challenges of translational science.

Authors:  Susan M Wolf
Journal:  Annu Rev Genomics Hum Genet       Date:  2013-07-15       Impact factor: 8.929

3.  Perceived ambiguity as a barrier to intentions to learn genome sequencing results.

Authors:  Jennifer M Taber; William M P Klein; Rebecca A Ferrer; Paul K J Han; Katie L Lewis; Leslie G Biesecker; Barbara B Biesecker
Journal:  J Behav Med       Date:  2015-05-24

Review 4.  Disorders of sex development: effect of molecular diagnostics.

Authors:  John C Achermann; Sorahia Domenice; Tania A S S Bachega; Mirian Y Nishi; Berenice B Mendonca
Journal:  Nat Rev Endocrinol       Date:  2015-05-05       Impact factor: 43.330

5.  A primer in genomics for social and behavioral investigators.

Authors:  Erin Turbitt; Barbara B Biesecker
Journal:  Transl Behav Med       Date:  2020-05-20       Impact factor: 3.046

Review 6.  Personal utility in genomic testing: a systematic literature review.

Authors:  Jennefer N Kohler; Erin Turbitt; Barbara B Biesecker
Journal:  Eur J Hum Genet       Date:  2017-03-15       Impact factor: 4.246

7.  Attitudes, knowledge and consequences of uncertain genetic findings in hypertrophic cardiomyopathy.

Authors:  Charlotte Burns; Laura Yeates; Catherine Spinks; Christopher Semsarian; Jodie Ingles
Journal:  Eur J Hum Genet       Date:  2017-05-03       Impact factor: 4.246

8.  Ability of Patients to Distinguish Among Cardiac Genomic Variant Subclassifications.

Authors:  Lydia D Hellwig; Barbara B Biesecker; Katie L Lewis; Leslie G Biesecker; Cynthia A James; William M P Klein
Journal:  Circ Genom Precis Med       Date:  2018-06

9.  Much ado about nothing: A qualitative study of the experiences of an average-risk population receiving results of exome sequencing.

Authors:  Shannon Rego; Orit Dagan-Rosenfeld; Stephanie A Bivona; Michael P Snyder; Kelly E Ormond
Journal:  J Genet Couns       Date:  2019-03-05       Impact factor: 2.537

10.  Informed consent for whole-genome sequencing studies in the clinical setting. Proposed recommendations on essential content and process.

Authors:  Carmen Ayuso; José M Millán; Marta Mancheño; Rafael Dal-Ré
Journal:  Eur J Hum Genet       Date:  2013-01-16       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.